Actively Recruiting
OM336 in Autoimmune Cytopenias
Led by Ouro Medicines · Updated on 2025-09-30
32
Participants Needed
3
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
CONDITIONS
Official Title
OM336 in Autoimmune Cytopenias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Active autoimmune cytopenia
- Relapsed or refractory after at least 1 prior treatment
- Body weight of 55 kg or more
- Willing to comply with study requirements and procedures
You will not qualify if you...
- Previous treatment with a BCMA-targeted therapy
- Clinically significant infection within 3 months before screening
- Major surgery or splenectomy within 3 months before screening or planned during the study
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The Canberra Hospital
Canberra, Australian Capital Territory, Australia, 2605
Actively Recruiting
2
Liverpool Hospital
Sydney, New South Wales, Australia, 2107
Actively Recruiting
3
Icon Cancer Center South Brisbane
Brisbane, Queensland, Australia, 4066
Actively Recruiting
Research Team
S
Study Sponsor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here